Peter N. Morcos
Bayer (United States)(US)Whipps Cross University Hospital(GB)Therapeutics Clinical Research(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Biosimilars and Bioanalytical Methods, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial(2021)395 cited
- → Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial(2010)336 cited
- → Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy(2019)256 cited
- → Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors(2012)43 cited
- → CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial(2018)32 cited
- → Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis